Table 2.
Summary of all ongoing trials using immune checkpoint inhibitors in combination with other agents in rrHL as of March 1st, 2018. BV = Brentuximab Vedotin; ICE = Ifosfamide, Carboplatin, and Etoposide; ISRT = Involved site radiation therapy.
| Combination ICI Clinical Trials | Phase | Trial ID |
|---|---|---|
| Nivolumab + Ipilimumab + BV | I | NCT01896999 |
| Nivolumab + Ipilimumab + Daratumumab | I | NCT01592370 |
| Nivolumab + Ipilimumab + Daratumumab + Pomalidomide | I | NCT01592370 |
| Nivolumab + Ibrutinib | II | NCT02940301 |
| Nivolumab + ICE chemotherapy | II | NCT03016871 |
| Pembrolizumab + ISRT | II | NCT03179917 |
| Pembrolizumab + AFM13 | I | NCT02665650 |
| Pembrolizumab + Lenalidomide | I/II | NCT02875067 |
| Pembrolizumab + ICE chemotherapy | II | NCT03077828 |
| Pembrolizumab + BV | III | NCT02684292 |
| Pembrolizumab + Vorinostat | I | NCT03150329 |
| Nivolumab + Bendamustine | I/II | NCT03343652 |